Recent News

• 03.31.2026 - MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
• 03.04.2026 - MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
• 03.03.2026 - MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
• 03.02.2026 - MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
• 02.24.2026 - MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
• 01.20.2026 - MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

Recent Filings

• 03.27.2026 - EX-99.1 EX-99.1
• 03.27.2026 - 8-K Current report
• 03.23.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2026 - EX-99.1 EX-99.1
• 03.04.2026 - 8-K Current report
• 03.04.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.02.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - 8-K Current report
• 01.20.2026 - EX-99.1 EX-99.1